Efficacy of Goshajinkigan for Oxaliplatin-Induced Peripheral Neuropathy in Colorectal Cancer Patients

Table 1

Characteristics of patients receiving Goshajinkigan for peripheral neuropathy due to oxaliplatin-based chemotherapy for colorectal cancer.

	GJG	Non-GJG	𝑃
Number	29	44
Age	60.4 ± 9.9	64.5 ± 11.6	N.S.
Sex (M/F)	17/12	26/18	N.S.
ECOG PS 0-1/2	25/4	40/4	N.S.
Ratio of stage 3/stage 4	7/22	13/31	N.S.
Ratio of FOLFOX/XELOX	17/12	25/19	N.S.
Median cumulative dose of oxaliplatin (mg)	1127 ± 390	1134 ± 487	N.S.

PS: performance status; GJG: Goshajinkigan; P: 𝑃 value; N.S.: not significant.